Start with the tell: in 2024, the prime-editing patents weren't mostly about whether the technique works. They were about making it work well. That shift — from concept to efficiency — is how you spot a maturing technology in the filing record.
Prime editing rewrites DNA letters directly instead of cutting both strands, which makes it precise but, historically, slow and low-yield. A field still proving the concept files broad mechanism claims. A field tuning a working tool files narrow improvement claims. By 2024, the balance had tipped to the latter.
Agilent's grant US11884915B2 on chemically modified guide RNAs for prime editing is exactly an efficiency claim — small molecular tweaks that make the edit take more reliably. Its companion US20240218354A1 covers the same modified-guide approach.
Other 2024 filings push reliability and yield. Publication US20240409907A1 covers improving prime-editing efficiency with cis-acting regulatory elements — bolting on sequence helpers that raise the editing rate. Multiple independent groups optimizing the same step is the trend signal.
The caveat stays the same: a count of efficiency patents tells you the technology is being refined, not that any prime-editing therapy has reached patients. Refinement is necessary but not sufficient.
By the numbers, though, 2024 reads as prime editing's coming-of-age in the patent record. The conversation in the filings moved from 'this is possible' to 'here's how to make it good enough' — and that's the conversation that precedes real-world use.